Objectives: Clinical manifestations of coronary heart disease result primarily from the progressive development of atherosclerotic plaques and subsequent thrombus formation; processes which may be accelerated by an enhanced expression of plasminogen activator Ž . inhibitor PAI-1 in the vessel wall. In the present study, content and expression of PAI-1 were comparatively analyzed in human coronary arteries in relation to the presence and severity of atherosclerotic lesions. Methods: Segments of coronary arteries obtained from Ž . heart explants n s 15 were classified by the presence and types of atherosclerotic lesions. Antigen and activity levels of PAI-1 were determined in protein extracts of intimal and medial layers. In situ hybridization and immunohistochemical analyses were performed on serial sections of representative tissue specimens. Results: Total PAI-1 antigen consistently increased from macroscopically normal areas Ž . Ž . Ž . Ž . MNAs to early lesions ELs and to maximal levels in fibrous FPs and calcified CPs plaques. No PAI activity was detected, although PAI-1 in its free form was present in all vascular specimens. Both free PAI-1 and PAI-1 complexed with plasminogen activators were significantly increased in extracts of advanced lesions. However, there was a 2-3 fold molar excess of free versus complexed PAI-1 in FPs and CPs. These findings suggest the presence of relevant amounts of PAI-1 in its substrate rather than in its inhibitor conformation in areas of advanced lesions. Compared with MNAs, PAI-1 mRNA was strongly expressed within the thickened intima of ELs. The highest PAI-1 expression was observed in FPs and CPs, being mainly localized in areas surrounding the necrotic cores in co-localization with infiltrating macrophages. Conclusions: PAI-1 content is consistently increased in relation to the severity of the lesions in atherosclerotic coronary arteries. The concomitant elevation of PAI-1 mRNA suggests that the PAI-1 increase is regulated by local synthesis in the areas of atherosclerotic lesions. q 1997 Elsevier Science B.V.
Introduction
Thrombus formation has been implicated as a major event responsible for the transformation of stable into active atherosclerotic lesions, leading to clinical manifestaw x tions in coronary heart disease 1,2 . Thrombotic vessel occlusion has been demonstrated in the majority of indiw x viduals with myocardial infarction 3,4 . Fibrin has also been found as a significant component in the intimal and subintimal layers of the arterial vessel wall with developw x ing atherosclerotic lesions 5 . Increasing evidence suggests a possible pathogenic role for intramural fibrin deposition. Fibrin might, indeed, influence atherogenesis through several mechanisms, e.g. by modulating endothew x lial cell permeability 6 , by providing a scaffold for w x smooth muscle cell migration and proliferation 7 , and through binding of atherogenic lipoproteins or thrombin w wx x reviewed in 8 .
Fibrin is mainly degraded by the plasminogen activa-( )Ž . w x torrplasmin PArplm system 9 . A reduced local activity of the PArplm system may predispose to the deposition of intramural and intraluminal fibrin in atherosclerotic coronary arteries. The activity of the PArplm system is highly regulated by the level of plasminogen activator Ž . inhibitor-1 PAI-1 , the major physiological inhibitor of Ž . Ž . tissue-type TPA -and urokinase-type UPA -plasminow x gen activators 9 . PAI-1, a serine proteinase inhibitor of the serpin group, may occur in three interconvertible conformations. Besides its active inhibitory form that spontaneously converts into the latent form, a third conformation w x as a non-inhibitory substrate has been identified 10,11 . The reaction of PAs with PAI-1 in its substrate form leads to the generation of a degraded PAI-1 without inhibition of the proteinase and without formation of a stable covalent w x complex in contrast to the active PAI-1 10 . In addition to PAs, other serine proteinases, like thrombin and elastases, are known to cleave and inactivate PAI-1 in its substrate w x form 12,13 . The association rate between thrombin and PAI-1 is highly enhanced in the presence of cofactors as the glycoprotein vitronectin or the glycosaminoglycan hepw w x x arin reviewed in 12 . Clinical studies have demonstrated elevated plasma levels of PAI-1 in patients with coronary artery disease w x 14-17 and in individuals at high risk of future myocarw x dial infarction 18, 19 . Evidence for a role of intravascular PAI-1 in atherogenesis is provided by experimental animal studies showing increased PAI-1 expression in aortic neointimal cells in response to sustained mechanical injury w x 20,21 , particularly when accompanied by hypercholesw x terolemia 21 . In human arteries, increased levels of PAI-1 w x w x mRNA 22,23 and antigen 24-26 have been found in severely atherosclerotic vessels compared with normal or only mildly affected arteries. The enhanced expression of PAI-1 has been localized to plaques and to thickened intima, mostly in association with macrophages and smooth w x muscle cells 22-29 .
The studies on human arteries, however, have been mainly performed on aortic, carotid, or peripheral tissue specimens. To date, only two recent reports have dealt with the immunolocalization of PAI-1 in human coronary w x arteries 30,31 . However, PAI-1 protein levels and PAI-1 mRNA expression have not been systematically studied. Thus, the present investigation was undertaken to analyze comparatively the content and activity state of intramural PAI-1 as well as the distribution of PAI-1 mRNA and antigen in human coronary arteries in relation to the presence and severity of atherosclerotic lesions.
Methods

Preparation of Õascular tissues
Epicardial coronary artery specimens were obtained from heart explants of 15 patients undergoing heart transplantation for end-stage congestive heart failure as conse- To confirm the validity of the macroscopic classification, representative sections of the different segments were examined by routine histochemical staining with hematoxylin-eosin and for cell identification by immunohistochemistry. Coronary artery segments for in situ hybridization, immunohistochemistry and routine histochemical analysis were fixed in neutral buffered 4% paraformaldehyde and embedded in paraffin before serially sectioned into 8 mm thick slices and mounted on STAR-Ž . FROST adhesive slides Engelbrecht . In the artery segments used for protein extraction, the adventitia layer was carefully dissected under a magnifier, and the intima-media specimens were immediately snap-frozen in liquid nitrogen and stored at y808C.
Tissue extraction
Intima-media specimens of coronary arteries were exw x tracted as described previously 24 . Briefly, individual tissue specimens were ground under liquid nitrogen until reduced to a fine powder, which was resuspended in Ž . ice-cold acid acetate buffer 20 mg wet tissuerml consisting of 75 mmolrl acetic acid, 225 mmolrl NaCl, 75 mmolrl KCl, 10 mmolrl EDTA, 100 mmolrl arginine, Ž . Ž . 0.25% vrv Triton X-100 final pH 4.2 . Samples were homogenized for 1 min at 48C. Tissue homogenates were then centrifuged for 10 min at 3000 = g, 48C. The super-Ž . natants were filtered Sartorius filter, pore size 1.2 mm and stored at y808C until assayed. In order to control for the efficiency of the extraction procedure, the protein concentration of each tissue extract was determined by the Ž . w x bicinchoninic acid BCA method 32 , using a commercial Ž . assay Pierce Chemical Co. . Since no significant differences in protein content of the extracts were observed Ž . between groups Kruskal-Wallis analysis, P s 0.306 , the results are presented per 100 mg wet tissue weight. The Ž . efficacy of the acid acetate buffer as used to extract PAI-1 in the free, active and PA-complexed forms was compared with the efficacies of the acetate buffer neutralized at pH 7 and the acetate buffer at acidic pH but in the The concentration of total PAI-1 antigen in the tissue Ž extracts was determined by a commercial ELISA Tinte-. lize, Biopool . In this assay, the capturing antibody is a Ž . mouse anti-PAI-1 monoclonal antibody MA-7D4B7 and the detecting antibody a goat polyclonal anti-human PAI-1 IgG. According to the manufacturer, the assay recognizes Ž . free active and latent and complexed PAI-1 to equal extent. For measurement of free PAI-1 levels a commercial Ž . ELISA Imulyse, Biopool employing two murine monoclonal antibodies MA-7D4 and MA-7F5 as coat and conjugate respectively, was used. This assay detects the various forms of human PAI-1 with the following efficiencies: latent 100%, active 83%, complexed 10%, and degraded w x 21% 34 . PAI-1rTPA complex was measured by a two-site Ž . ELISA Asserachrom, Stago , using a monoclonal mouse anti-TPA as capture antibody and a monoclonal anti-PAI-1 as detecting antibody. The working range of the ELISA for the measurement of PAI-1rTPA was 0.04 to 1.5 ngrml Ž . expressed as TPA equivalent . The two-site ELISA for measurement of PAI-1rUPA complex utilized a mouse Ž monoclonal anti-human UPA as capture antibody MUK-1, . Biopool and a mouse monoclonal anti-human PAI-1 bi-Ž otin conjugate as detecting antibody PAI-1 ELISA kit, . Monozyme . As standard, PAI-1rUPA complex was prepared by incubation of 10 nmolrl two-chain active UPA Ž . purified from human urine; Calbiochem with a 50-fold Ž molar excess of active PAI-1 recombinant, human; Cal-. Ž . biochem at room temperature RT for 60 min. The absence of free UPA in the incubates was controlled w x spectrophotometrically 35 . For the standard curve, the PAI-1rUPA preparation was used in a range of 0.05 to 2 ngrml. The assay did not recognize free UPA or PAI-1 even at 200 fold higher concentrations than the highest concentration of the standard curve. The intraassay and interassay variations were below 10%.
Assay of PAI actiÕity
PAI activity was evaluated spectrophotometrically as w x described by Verheijen et al. 36 .
Preparation of PAI-1 cRNA probes
A 1977-bp cDNA probe for human-PAI-1 inserted in Ž . the pGEM3Z vector Promega , kindly provided by Dr. P. Ž Quax Gaubius Laboratory TNO, Leiden, The Nether-. lands , was used. Antisense and sense cRNA probes were transcribed in vitro from linearized plasmids using digoxi-Ž . genin-labeled UTP Boehringer Mannheim and SP6-or Ž . T7-RNA polymerase Boehringer Mannheim , respectively. Correct synthesis of the cRNA probes was controlled by agarose-gel electrophoresis. RNA probes were cut into 400-up to 500-bp fragments by limited alkaline hydrolysis in 40 mmolrl NaHCO r60 mmolrl Na CO , 3 2 3 pH 10.2.
In situ hybridization
Ž . In situ hybridization ISH was performed as described w x by Wilcox et al. 37 
Immunohistochemistry
Serial sections adjacent to those used for in situ hybridization were processed for immunohistochemical detection of PAI-1 antigen and identification of macrophages, smooth muscle and endothelial cells. The following murine Ž monoclonal antibodies were used: anti-human PAI-1 Mab . 3785, American Diagnostica; 20 mgrml , anti-human Ž macrophage DAKO-CD68, DAKO; working dilution . Ž 1:50 , anti-human a-smooth muscle actin clone 1A4, . DAKO; working dilution 1:25 , anti-human von Wille-Ž . brand factor DAKO-vWF, DAKO; working dilution 1:25 .
Ž . For negative controls mouse IgG Sigma; 20 mgrml was used in substitution of the first antibody. Immunohistolo-( )calization was performed by the peroxidase conjugated w x biotin-avidin technique as described previously 24 .
Statistics
Data are presented as individual data plots or as medians and interquartile ranges. Statistical significance of overall differences between groups was analyzed by the Kruskal-Wallis one-way analysis. If the test was significant, pairwise comparisons were done by the multiplew x comparisons' criterion 39 . The Wilcoxon matched-pairs signed rank test was used to compare levels of free and complexed PAI-1 in each group. A P value of 0.05 or less was considered significant.
Results
Ž
For the determination of PAI-1 total, free, complexed, . and active in intima-media extracts, coronary arteries with Ž . macroscopically normal areas MNAs and with each of Ž the different types of atherosclerotic lesions ELs, FPs, and . CPs were available from seven heart explants of patients with end-stage clinical ischemic cardiac disease. Representative segments of each category were isolated and extracted separately. However, depending on the size of the tissue samples, representative artery segments of the same category and from the same individual explant were pooled for tissue homogenization and extraction. For in situ hybridization and immunohistolocalization of PAI-1, coro-Ž . Ž . nary segments with MNAs n s 5 , ELs n s 6 and FPs Ž . or CPs n s 5 were obtained from eight additional heart explants. Four of 5 MNAs specimens, two of 6 ELs and one of 5 FPs were retrieved from patients with dilative Ž . cardiomyopathy n s 4 as the cause for the failing heart. The remaining specimens were obtained from patients with Ž . end-stage ischemic cardiac disease n s 4 .
Histological characterization of the atherosclerotic lesions
Histological examination of the coronary artery specimens confirmed that very little or no intimal thickening existed in segments with MNAs. The endothelium was intact in these segments as detected by immunostaining for von Willebrand factor. Occasional cells staining positive for a-actin, but no infiltrating CD68-positive macrophages were detected in the intima. Coronary artery segments with early atherosclerotic lesions exhibited the characteristic thickening of the tunica intima. a-Actin immunostaining was found throughout the subendothelial intima indicating that a significant proportion of the cells in the intimal layer were SMCs. Scattered CD68-positive macrophages were localized immediately beneath the luminal endothelium, which was found always intact in segments with ELs. Fibrous and calcified plaques consistently contained a well-defined core region of amorphous material. Lesions with evidence of haematomas or thrombotic deposits were excluded from the analyses. Luminal endothelium was frequently absent in this type of lesions, and immunohistochemical staining identified SMCs and macrophages as the principal cellular elements. The latter cells mainly concentrated at the adjacent sides of the core regions.
PAI-1 leÕels in coronary artery extracts
The amount of extractable total PAI-1 antigen consistently increased from macroscopically normal areas to early lesions to maximal levels in fibrous and calcified Ž . plaques Fig. 1 ; Kruskal-Wallis analysis: P -0.001 . This trend was observed for each individual heart explant and regardless of whether the results were expressed as total Ž PAI-1 antigen per mg of wet tissue extracted as pre-. Ž . sented or per amount of extractable protein not shown . The difference in PAI-1 content between MNAs and advanced lesions was highly significant as was the difference Ž between ELs and CPs P values by multiple group comparisons' criterion: MNAs versus FPs s 0.025; MNAs ver-. sus CPs s 0.001; ELs versus CPs s 0.025 .
To determine the levels of free and PA-complexed PAI-1, tissue extracts were analyzed by different im- Fig. 1 . Total PAI-1 antigen in intima-media extracts of coronary artery segments with different types of atherosclerotic lesions. Results are Ž . expressed in fmol per 100 mg wet tissue wt extracted. Coronary arteries from ns 7 individual heart explants were analyzed. Representative segments of each type of lesions were available from all but one explant, where a CP for tissue extraction was not obtainable. Data points represent individual values in each group and those linked by lines originate from the same heart explant. Significance testing for overall group differences Ž . was performed by the Kruskal-Wallis test P -0.001 . The multiplecomparisons' criterion was employed to identify differences between Ž groups. The w denotes a significant increase versus the MNA group FP: . Ž P s 0.025, CP: P s 0.001 and the ' versus the EL group CP: P s . 0.025 . Ž . Fig. 2 . Levels of free PAI-1 A and PAI-1 complexed with PAs B in intima-media extracts of coronary arteries with different types of atherosclerotic lesions. Points linked by lines represent data from the same heart explant. Overall group differences were tested for statistical significance Ž by Kruskal-Wallis analysis free PAI-1: P s 0.004; PAI-1rPA complex:
. P s 0.005 . Subsequent pairwise group comparisons using the multiple Ž . comparisons' criterion revealed: A a significant difference between CPs Ž . Ž . and MNAs P s 0.01 denoted by w , B a significant difference be-Ž . tween CPs and MNAs P s 0.005; denoted by w and between CPs and Ž . ELs P s 0.05; denoted by ' . munoassays. A similar, though less marked trend as for Ž . total PAI-1 was found for free PAI-1 antigen Fig. 2A measured by an ELISA which recognizes specifically law x tent and active PAI-1 34 . Significant overall group differ-Ž ences were confirmed by Kruskal-Wallis analysis P s . 0.004 . Subsequent multiple group comparisons revealed a significant increase in extractable free PAI-1 in areas with Ž . CPs compared with MNAs P s 0.01 . Levels of PAI-1 complexed with PAs were expressed as the sums of PAI1rTPA and PAI-1rUPA concentrations. As shown in Fig.  2B , the content of PAI-1rPA complex was slightly but significantly increased in atherosclerotic segments of coro-Ž . nary arteries Kruskal-Wallis test: P s 0.005 . The me-Ž . dian value for CPs 193.5 fmolr100 mg tissue was Ž significantly higher than for MNAs 104.5 fmolr100 mg . Ž tissue; P s 0.005 and for ELs 106.0 fmolr100 mg tis-. sue; P s 0.05 . Separate data for PAI-1rTPA and PAI1rUPA complex in the coronary extracts are shown in Table 1 . Free and complexed PAI-1 were found in equimolar concentrations in extracts of MNAs and ELs, but the Using a spectrophotometric assay, we did not detect PAI activity in any of the coronary artery extracts analyzed. Transformation of active into latent PAI-1 during the extraction procedure was excluded in previous experiw x ments 24 . PAI-1 activity was neither detected when coronary artery tissues were extracted with neutralized acetate buffer nor when pepstatin A was added to the acid acetate buffer. The extraction of coronary tissue at neutral pH or at acidic pH in the presence of pepstatin A did not affect the relative levels of free and complexed PAI-1 in Ž . the extracts Table 2 . According to these results, an underestimation of active PAI-1 due to lysosomal degrada-Ž . tion encouraged by the acidic pH of the buffer during the extraction procedure is unlikely to have occurred.
PAI-1 localization in coronary artery sections
Representative specimens of normal areas and of atherosclerotic lesions were serially sectioned and processed in parallel for in situ hybridization and immunohistochemical analyses. Table 2 The indicated numbers are the means"SD obtained by three separate extractions with each buffer.
The luminal endothelium in MNAs and ELs stained Ž . positive for PAI-1 mRNA Fig. 3A and 3D . In the medial layer, in situ hybridization analysis revealed a widespread distribution of positive signals for PAI-1 mRNA, but the Ž . staining was markedly enhanced in ELs Fig. 3A and 3D . In addition, PAI-1 was strongly expressed within the thick-Ž . ened intima of ELs Fig. 3D in cell-rich The findings reported on advanced atherosclerotic le-Ž sions apply to fibrous and to calcified plaques Fig. 3, G . through I . In these areas, PAI-1 mRNA was highly expressed compared with MNAs and ELs. PAI-1 mRNA specific signals were observed throughout the fibrous cap and in the base of the lesions in co-localization with Ž . a -positive staining for SMCs not shown . However, PAI-1 mRNA signals were particularly intense in regions adja-Ž . cent to the necrotic cores Fig. 3G , in cell-rich areas which also stained intensively for CD68-positive Ž . macrophages not shown . Some PAI-1 antigen staining was detected in the cap at sides of mRNA expression, but the strongest PAI-1 antigen signal was detected in the core of the lesions, in areas mainly containing amorphous mate-Ž . rial Fig. 3I .
Controls for in situ hybridization using a sense cRNA Ž . probe Fig. 3B , 3E and 3H and for immunostaining using nonimmune murine IgG in substitution for first antibodies Ž . not shown were consistently negative.
Discussion
Clinical manifestations of coronary heart disease result primarily from the progressive development of atherosclerotic plaques and subsequent thrombus formation. Expression of PAI-1 in the arterial vessel wall has been postulated to play an important role in atherogenesis and mural thrombosis. Up to now, only two studies have dealt w x with PAI-1 expression in human coronary arteries 30,31 . Using immunohistochemistry, both studies detected PAI-1 immunoreactivity in normal and diseased vessel walls.
The present investigation, based on quantitative protein determinations in extracts of coronary arteries, unambiguously demonstrates a consistent increase of PAI-1 content Ž . total, free and PA-complexed from macroscopically normal areas to early lesions and to peak values in advanced atherosclerotic plaques. These results are in line with those reported before by our group and others on human aortic w x tissue 24-26 . Furthermore, in the intima and media of atherosclerotic human coronary arteries Raghunath et al. w x 31 detected a widespread staining for PAI-1, with a trend towards more intense staining in the endothelium of areas with plaques. However, our study is the first that quantitates PAI-1 protein comparatively in various types of atherosclerotic lesions isolated from coronary arteries obtained from individual heart explants.
In the extracts of macroscopically normal areas, free and PA-complexed forms of PAI-1 were in equimolar concentrations and almost quantitatively accounted for the total level of PAI-1 antigen. Despite the presence of free PAI-1, we were unable to detect PAI activity in the intima-media extracts of MNAs by a spectrophotometric assay. These results suggest that free PAI-1 is mainly in its latent form in these areas. Following activation of latent PAI-1 within the coronary vessel wall, e.g. by negatively w x charged phospholipids 40,41 , active PAI-1 becomes rapidly inactivated by complex formation with PAs.
In extracts of early and advanced atherosclerotic lesions, the sum of free PAI-1 and PAI-1rPA contents did not exceed 65% of the total PAI-1 antigen concentration. This may indicate the presence of substantial amounts of degraded PAI-1 in these areas, which was not recognized w x by the immunoassay for free PAI-1 34 . In addition, we have found a 2-3 fold molar excess of free versus PAcomplexed PAI-1, but no PAI activity in the extracts of advanced atherosclerotic lesions. Taking these results together, we hypothesize that in atherosclerotic lesions of human coronary arteries a relevant amount of PAI-1 is in its substrate rather than in its inhibitor conformation for w x PAs 10 . The excess of total PAI-1 antigen compared with the sum of free and PA-complexed PAI-1 could be explained by an enhanced cleavage and degradation of PAI-1 in its substrate form. The potential enzymes that cleave PAI-1 could be thrombin with vitronectin as cofactor, since both components are localized in atherosclerotic w x lesions 42,43 , or elastase released by leucocytes derived w x from microthrombi incorporated into the vessel wall 44 .
The lack of PAI activity in the extracts of coronary ( )atherosclerotic lesions is consistent with the excess of extractable PA activity reported in atherosclerotic coronary w x specimens 45,46 . It is interesting to note that an opposite fibrinolytic profile exists in the human aortic vessel wall, where excess of PAI activity is present in the intimal and w x medial layers 24 . The present data corroborate our previous suggestion that quantitative differences in the modulation of intramural PAs by PAI-1 exist between coronary and aortic vessel walls.
Our data on PAI-1 mRNA distribution in atherosclerotic coronary arteries are consistent with the previous reports in w x aorta, carotid, and peripheral arteries 22,23,26-28 . They confirm the presence of PAI-1 mRNA in the luminal endothelium and throughout the medial layer both in normal and atherosclerotic segments. Furthermore, they corroborate the detection of widespread PAI-1 mRNA within the thickened intima of ELs in co-localization with intimal smooth muscle cells. In advanced lesions, intense hybridization signals for PAI-1 were observed in the cap and in areas adjacent to the necrotic cores, mainly in association with infiltrates of macrophage-like cells. The increased PAI-1 expression in the cap of the fibrous plaques in coronary arteries is in accordance with the findings in aorta reported by previous studies. However, in the cap of advanced aortic atherosclerotic lesions PAI-1 expression w x was mainly related to SMCs 22,27 . In contrast to MNAs and ELs where PAI-1 antigen was co-localized with sides of mRNA expression, in advanced lesions there was a discrepancy in the distribution pattern between synthesis and localization of PAI-1. The accumulation of PAI-1 antigen in the necrotic core suggests that after secretion from cells, e.g. macrophages, PAI-1 becomes locally concentrated by binding to extracellular matrix proteins, most likely fibrin and vitronectin, which also have been detected w x in these areas 8, 43 .
Mural TPA and UPA may affect atherogenesis through a variety of mechanisms that include fibrin digestion, w x regulation of growth factor activities 47 , and extracellular w x matrix degradation 48 . Local content and conformation of PAI-1 in the vessel wall are of great interest because of its function in regulating the activities of mural PAs. A local increase of PAI-1 in the inhibitory conformation may promote coronary atherogenesis by predisposing to local thrombosis and fibrin deposition. On the other hand PAI-1 as an inhibitor may contribute to plaque stabilization. The conformational change of PAI-1 towards its substrate form may represent a regulatory mechanism as well. Since PAI-1 in its substrate conformation is susceptible for proteolytic degradation, it could increase the local concentration of free PAs and subsequently promote plasmin generation, w x as has been demonstrated in studies in vitro 49 . This could represent a protective mechanism by increasing fibrin degradation, but in turn an enhanced plasmin formation in advanced atherosclerotic plaques could lead to extracellular matrix breakdown and therefore might contribute to plaque destabilization.
In conclusion, our results demonstrate a consistent increase of PAI-1 content in relation to the presence and severity of atherosclerotic lesions in human coronary arteries. The concomitant elevation of PAI-1 mRNA suggests that the quantitative alterations in PAI-1 content are regulated by local synthesis in the areas of lesion. Further studies are necessary to elucidate the role of the different forms of PAI-1 in atherogenesis. 
